Posted Feb. 10, 2012 at 7:10 a.m.

Premium Lock $40M Aldagen deal is no quick exit for its investors

Published: 2012-02-10 07:10:57
Updated: 2012-02-10 07:10:57

Aldagen's pipeline Aldagen's pipeline Image 1 of 2 · Next Image…

Aldagen, who had tried twice to go public only to withdraw both times amid poor market conditions, gets a partner interested in developing its stem cell treatments. Cytomedix gains prospective regenerative medicine therapies for its pipeline. But a payoff remains in the future and depends on drug trial results....

Read More
Read More

Copyright 2014 MedCity. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Best of TechWire Insider

Techwire Inside Partners

OUR INSIDERS

Vivek Wadhwa
Commentary
Dr. Mike Walden
Tech economy
Frank Vinluan
Life science
Scroll